

PROVIDER BULLETIN

PROVIDER INFORMATION



May 1, 2024

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-004	Minimally Invasive Approaches to Vertebral Fractures
MP-081	Allergy Immunotherapy
MP-513	Genetic Testing for Hereditary Breast and/or Ovarian Cancer
MP-527	Bio-Engineered Skin and Soft Tissue Substitutes
MP-597	Amniotic Membrane and Amniotic Fluid
MP-758	Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90349	Hemophilia Products –Anti-Inhibitor Antibody: Hemlibra (emicizumab-kxwh)
PH-90696	Lamzedo (velmanase-alfa-tycv)
PH-90183	Levoleucovorin: Fusilev; Khapzory
PH-90146	Xolair (omalizumab)
PH-90748	Amtagvi (lifileucel)